CYP2C8 rs1934980 — Intronic Variant Shaping Drug Metabolism and Bone Risk
CYP2C811 CYP2C8
Cytochrome P450 family 2, subfamily C, member 8 — a liver enzyme responsible
for metabolizing roughly 5% of marketed drugs
is a workhorse of hepatic drug clearance. Unlike its close relative CYP2C9, CYP2C8
handles a distinct substrate portfolio: the cancer drug paclitaxel, the diabetes drugs
rosiglitazone and repaglinide, the antimalarial amodiaquine, and the NSAIDs ibuprofen
and diclofenac. Beyond drug metabolism, CYP2C8 converts arachidonic acid into
epoxyeicosatrienoic acids (EETs)22 epoxyeicosatrienoic acids (EETs)
signaling lipids with anti-inflammatory and
vasodilatory properties, making it
relevant to cardiovascular homeostasis.
The Mechanism
rs1934980 sits within an intron of CYP2C8 on chromosome 10 (GRCh38 position 95,049,216).
Intronic variants can affect mRNA splicing efficiency, transcription factor binding sites,
or enhancer activity, all of which alter enzyme expression levels without changing the
protein's structure. The G allele falls within a haplotype cluster — rs1934951,
rs1934980, rs1341162, and rs17110453 — that segregates together across the CYP2C8 gene
due to linkage disequilibrium33 linkage disequilibrium
tendency for nearby variants to be inherited as a unit
rather than independently.
The Evidence
The most compelling clinical signal comes from a 2008 genome-wide SNP study by
Sarasquete et al.44 Sarasquete et al.
Blood, 2008 that
examined 22 multiple myeloma patients with bisphosphonate-related osteonecrosis of the
jaw (BRONJ) against 65 matched controls. Among four significant CYP2C8 variants,
rs1934980 showed p = 4.2×10⁻⁶ between cases and controls. The biological plausibility
rests on CYP2C8's role in production of EETs that protect bone vasculature. Follow-up evidence is mixed:
Such et al. (2011)55 Such et al. (2011)
Haematologica, n=79
could not replicate the association for rs1934951, though a meta-analysis (2013)66 meta-analysis (2013)
Zhong et al., Acta Haematol recovered a
significant signal for rs1934951 in multiple myeloma patients specifically
(dominant model OR=5.77, p=0.028). Because rs1934980 is in strong LD with rs1934951,
its effect likely tracks the same haplotype.
The clopidogrel connection emerged in a 2024 pharmacogenomic polygenic study of
935 Chinese CAD patients77 935 Chinese CAD patients
Zhang et al., Clinical Therapeutics
where rs1934980 was nominally associated with recurrent ischemic events — consistent
with CYP2C8 contributing to the metabolic conversion of clopidogrel's intermediate
forms. The overall polygenic model predicted a hazard ratio of
1.87 for high risk-allele burden (p=0.04), though the individual variant contribution
was not reported separately.
Practical Actions
Carriers of one or two G alleles at rs1934980 should be aware of this variant's relevance to their medication history. If ever receiving intravenous bisphosphonates (zoledronic acid, pamidronate) for cancer-related bone disease or osteoporosis, the association with BRONJ risk warrants heightened dental surveillance. The cardiovascular relevance — through both clopidogrel response and EET production — makes this variant one to flag for cardiologists managing antiplatelet therapy in homozygous G carriers.
Interactions
rs1934980 is in strong linkage disequilibrium with rs1934951, rs1341162, and rs17110453 — all four variants were co-identified in the Sarasquete BRONJ GWAS and likely travel together as a CYP2C8 intronic haplotype. The combined effect of carrying this CYP2C8 haplotype alongside impaired CYP2C19 function (rs4244285, rs4986893) could compound altered clopidogrel activation, since both enzymes contribute to the drug's bioactivation pathway. An interaction with CYP2C9 variants (rs1799853, rs1057910) is also plausible for shared NSAID substrates.